Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary purpose: To investigate the effect of propolis, a food supplement product, on healing parameters in patients with COVID 19. Secondary purpose: To provide a new supportive treatment in Covid 19 treatment. In the present study to examine the effect of the use of propolis on healing parameters (laboratory and imaging) in patients with COVID 19; Propolis, which has antiviral properties, has also been used in humans in the COVID19 pandemic as of 2020. However, in these studies, an alcohol-soluble extract of propolis was used. Despite the disadvantages of its use in alcohol, it is clear that water and olive oil extracts of Propolis are safer for humans. Therefore, water extracts of propolis will be used in the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| water extract of propolis | Experimental | Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week |
|
| olive oil extract of propolis including perga | Experimental | Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week |
|
| control | No Intervention | control group (patients not given any investigational product) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| propolis | Dietary Supplement | Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules |
|
| Measure | Description | Time Frame |
|---|---|---|
| radiological | Lung tomography findings | Change from Baseline Lung Tomography Findings(Peripheral ground-glass opacities) at one week |
| laboratory parameters-2: ESR | ESR | Change from Baseline ESR findings at one week |
| laboratory parameters-3: CRP | CRP | Change from Baseline CRP findings at one week |
| laboratory parameters-4: D-Dimer | D-Dimer | Change from Baseline D-Dimer findings at one week |
| laboratory parameters-5: Troponin | Troponin | Change from Baseline Troponin findings at one week |
| laboratory parameters-6: sO2 | sO2 | Change from Baseline sO2 findings at one week |
| laboratory parameters-1: CBC | CBC | Change from Baseline CBC findings at one week |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Betül Değer Kulaksız, M.D | Trabzon Kanuni Education and Research Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Trabzon Faculty of Medicine , Health Science University | Trabzon | 61080 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32890967 | Background | Berretta AA, Silveira MAD, Condor Capcha JM, De Jong D. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. Biomed Pharmacother. 2020 Nov;131:110622. doi: 10.1016/j.biopha.2020.110622. Epub 2020 Aug 17. | |
| 32945590 | Background |
Not provided
Not provided
Individual participant data will not be shared.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D011429 | Propolis |
| ID | Term |
|---|---|
| D012116 | Resins, Plant |
| D001704 | Biopolymers |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
Not provided
Not provided
first group treated with water extracts of propolis second group treated with olive oil extracts of propolis including perga third group treated with no bee product
Not provided
Not provided
Not provided
Not provided
| Lima WG, Brito JCM, da Cruz Nizer WS. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2). Phytother Res. 2021 Feb;35(2):743-750. doi: 10.1002/ptr.6872. Epub 2020 Sep 18. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D053147 |
| Plant Exudates |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |